Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.69 |
| ▸ | HRH1 | P35367 | 3/20 | 0.69 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.69 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzopyrronium SCHEMBL916243 | 0.99 | CHRM3 (0.85) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Parapenzolate SCHEMBL14547205 | 0.93 | CHRM3 (0.73) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL44191 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL2994933 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL17071946 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Parapenzolate SCHEMBL636125 | 0.91 | CHRM3 (0.74) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL99030 | 0.91 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL15575981 | 0.91 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL17008166 | 0.91 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| Mepenzolate SCHEMBL147471 | 0.91 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |